Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: Implications for cancer treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 4, 2014, Pages 559-577

  Veenman, Leo ^a   Gavish, Moshe ^a   Kugler, Wilfried ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

18 kDa translocator protein (TSPO); ATP; Cardiolipin; Erucylphosphohomocholine (ErPC3; Erufosine); Glioblastoma; Mitochondrial apoptosis; Mitochondrial membrane potential ( m); Reactive oxygen species (ROS)

Indexed keywords

18 KDA TRANSLOCATOR PROTEIN; APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CARDIOLIPIN; CASPASE 3; CASPASE 8; CETUXIMAB; CHOLINE DERIVATIVE; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; CYTOCHROME C; DEATH LIGAND; DEATH RECEPTOR; ERUCYLPHOSPHOHOMOCHOLINE; ILMOFOSINE; MAMMALIAN TARGET OF RAPAMYCIN; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; PERIFOSINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCASPASE 9; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING KINETICS; CANCER THERAPY; CARCINOGENICITY; CELL PROLIFERATION; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; LIPID OXIDATION; LOSS OF APPETITE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL MEMBRANE; ERUCIC ACIDS; GLIOBLASTOMA; HUMANS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASMS; PHOSPHORYLCHOLINE; RECEPTORS, GABA; SIGNAL TRANSDUCTION;

EID: 84908148017     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140309230338     Document Type: Article

References (254)

1. Ohgaki, H.; Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol. (Berlin), 2005, 9, 93-108.
2. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
3. Strik, H.; Deininger, M.; Streffer, J.; Grote, E.; Wickboldt, J.; Dichgans, J.; Weller, M.; Meyermann, R. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J. Neurol. Neurosurg. Psychiatry, 1999, 67, 763-768.
4. Ruano, Y.; Mollejo, M.; Camacho, F.I.; Rodríguez de Lope, A.; Fiaño, C.; Ribalta, T.; Martínez, P.; Hernández-Moneo, J.L.; Meléndez, B. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. Cancer, 2008, 112, 1575-1584.
5. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov., 2010, 9, 447-464.
6. Galluzzi, L.; Morselli, E.; Kepp, O.; Vitale, I.; Rigoni, A.; Vacchelli, E.; Michaud, M.; Zischka, H.; Castedo, M.; Kroemer, G. Mitochondrial gateways to cancer. Mol. Aspects Med., 2010, 31, 1-20.
7. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 2007, 87, 99-163.
8. Hilgard, P.; Klenner, T.; Stekar, J.; Unger, C. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother. Pharmacol., 1993, 32, 90-95.
9. Lemeshko, V.V.; Kugler, W. Synergistic inhibition of mitochondrial respiration by anticancer agent erucylphosphohomocholine and cyclosporin A. J. Biol. Chem., 2007, 282, 37303-37307.
10. Munder, P.G.; Modolell, M.; Andreesen, R.; Weltzien, H.U.; Westphal, O. Lysophosphatidylcholine (lysolecithin) and its synthetic analogs. Immunomodulating and other biologic effects. Springer Sem. Immunopathol., 1979, 2, 187-203.
11. Berdel, W.E.; Greiner, E.; Fink, U.; Zänker, K.S.; Stavrou, D.; Trappe, A.; Fahlbusch, R.; Reichert, A.; Rastetter, J. Cytotoxic effects of alkyl-lysophospholipids in human brain tumor cells. Oncology, 1984, 41, 140-145.
12. Mollinedo, F.; Fernandez-Luna, J.L.; Gajate, C.; Martin-Martin, B.; Benito, A.; Martinez-Dalmau, R.; Modolell, M. Selective induction of apoptosis in cancer cells by the ether lipid ET18-OCH3 (Edelfosine): Molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res., 1997, 57, 1320-1328.
13. Arnold, B.; Reuther, R.; Weltzien, H.U. Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim. Biophys. Acta, 1978, 530, 47-55.
14. Magistrelli, A.; Villa, P.; Benfenati, E.; Modest, E.J.; Salmona, M.; Tacconi, M.T. Fate of 1-O-octadecyl-2-O-methyl-racglycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver. Drug Metab. Dispos., 1995, 23, 113-118.
15. Girgert, R.; Schweizer, P.; Bock, I.; Narr, R.; Bruchelt, G. Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells. J. Cancer Res. Clin. Oncol., 1995, 121, 262-266.
16. Giantonio, B.J.; Derry, C.; McAleer, C.; McPhillips, J.J.; O'Dwyer, P.J. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Clin. Cancer Res., 2004, 10, 1282-1288.
17. Ries, U.J.; Fleer, E.A.M.; Breiser, A.; Unger, C.; Stekar, J.; Fenneberg, K.; Eibl, H. In vitro and in vivo antitumoral activity of alkylphosphonates. Eur. J. Cancer, 1992, 29A, 96-101.
18. Sobottka, S.B.; Berger, M.R.; Eibl, H. Structure-activity relationship of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int. J. Cancer, 1993, 53, 418-425.
19. Kötting, J.; Berger, M.R.; Unger, C.; Eibl, H. Alkylphosphocholines: influence of structural variation on biodistribution at anti-neoplastically active concentrations. Cancer Chemother. Pharmacol., 1992, 30, 105-112.
20. Erdlenbruch, B.; Jendrossek, V.; Gerriets, A.; Vetterlein, F.; Eibl, H.; Lakomek, M. Erucylphosphocholine: Pharmacokinetics, biodistribution, CNS-accumulation and toxicity in the rat after intravenous application. Cancer Chemother. Pharmacol., 1999, 44, 484-490.
21. Ergezinger, K.; Vehmeyer, K.; Unger, C. Stimulation of human hematopoietic progenitor cells by the alkylphosphocholines hexadecylphosphocholine and hexadecyl-N,N,N-trimethyl-hexanolamine. Anticancer Res., 1999, 19, 3213-3219.
22. Berkovic, D.; Bensch, M.; Bertram, J.; Wille, T.; Haase, D.; Binder, C.; Fleer, E.A.M. Effects of hexadecylphosphocholine on thrombocytopoiesis. Eur. J. Cancer, 2001, 37, 503-511.
23. Unger, C.; Damenz, W.; Fleer, E.A.; Kim, D.J.; Breiser, A.; Hilgard, P.; Engel, J.; Nagel, G.; Eibl, H. Hexadecylphosphocholine, a new ether lipid analog. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol., 1989, 28, 213-217.
24. Wang, Y.Z.; Liu, X.Y.; Wu, L.J.; Zhang, Y.B.; Hou, L.; Xu, Q.S. Antiproliferation effects of hexadecylphosphocholine on solid tumour and leukaemia selectively in vitro. Drugs Exp. Clin. Res., 1997, 23, 97-102.
25. Jendrossek, V.; Erdlenbruch, B.; Hunold, A.; Kugler, W.; Eibl, H.; Lakomek, M. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int. J. Oncol., 1999, 14, 15-22.
26. Rybczynska, M.; Spitaler, M.; Knebel, N.G.; Boeck, G.; Grunicke, H.; Hofmann, J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol., 2001, 62, 765-772.
27. Kötting, J.; Marschner, N.W.; Neumüller, W.; Unger, C.; Eibl, H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: A comparison of hemolytic activity, serum binding and tissue distribution. In: Alkylphosphocholines: New Drugs in Cancer Therapy. Eibl, H.; Hilgard, P.; Unger, C., Eds.; Karger: Basel, 1992; Vol. 34, pp. 131-142.
28. Kaufmann-Kolle, P.; Kötting, J.; Drevs, J.; Berger, M.R.; Unger, C.; Eibl, H. Intravenous application of alkylphosphocholines: comparison of different homologues in lamellar structures. J. Cancer Res. Clin. Oncol., 1992, 120(Suppl), R14.
29. Eibl, H.; Kaufmann-Kolle, P. Medical application of synthetic phospholipids as liposomes and drugs. J. Liposome Res., 1995, 5,131-148.
30. Kaufmann-Kolle, P.; Drevs, J.; Berger, M.R.; Kötting, J.; Marschner, N.; Unger, C.; Eibl, H. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol., 1994, 34, 393-398.
31. Berdel, W.E.; Becher, R.; Edler, L.; Bremer, K.; Essers, U.; Drozd, A.; Zafferani, M.; Klee, M.A.G.; Bachmann, P.; Korfel, A.; Westerhausen, M. Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced non-small cell lung cancer. A phase II study. Onkologie, 1992, 15, 238-242.
32. Planting, A.; Stoter, G.; Verweij, J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer, 1993, 29A, 518-519.
33. Verweij, J.; Planting, A.; Van der Burg, M.; Stoter, G. A dose finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J. Cancer Res. Clin. Oncol., 1992, 118, 606-608.
34. Leonard, R.; Hardy, J.; Van Tienhoven, G.; Houston, S.; Simmonds, P.; David, M.; Mansi, J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol., 2001, 19, 4150-4159.
35. Berman, J.J. Treatment of leishmaniasis with miltefosine: 2008 status. Exp. Opin. Drug Metab. Toxicol., 2008, 9,1209-1216.
36. Hilgard, P.; Stekar, J.; Klenner, T.; Nössner, B.; Kutscher, B.; Engel, J. Heterocyclic alkylphospholipids with an improved therapeutic range. Adv. Exp. Med. Biol., 1996, 416, 157-164.
37. Crul, M.; Rosing, H.; De Klerk, G.J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N.G.; Schellens, J.H.; Beijnen, J.H.; Huinink, W.W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer, 2002, 38, 1615-1621.
38. Gills, J.J.; Dennis, P.A. Perifosine: Update on a novel Akt inhibitor. Curr. Oncol. Rep., 2009, 11, 102-110.
39. Li, X.; Luwor, R.; Lu, Y.; Liang, K.; Fan, Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene, 2006, 25, 525-535.
40. Kaufmann-Kolle, P.; Berger, M.R.; Unger, C.; Eibl, H. Systemic administration of alkylphosphocholines: Erucylphosphocholine and liposomal hexadecylphosphocholine. Adv. Exp. Med. Biol., 1996, 416, 165-168.
41. Berger, M.R.; Sobottka, S.; Konstantinov, S.M.; Eibl, H. Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs of Today, 1998, 34 (Suppl. F), 73-81.
42. Jendrossek, V.; Hammersen, K.; Erdlenbruch, B.; Kugler, W.; Krügener, R.; Eibl, H.; Lakomek, M. Structure-activity relationships of alkylphosphocholine derivatives: Antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother. Pharmacol., 2002, 50, 71-79.
43. Erdlenbruch, B.; Jendrossek, V.; Marx, M.; Hunold, A.; Eibl, H.; Lakomek, M. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res., 1998; 18, 2551-2557.
44. Konstantinov, S.M.; Eibl, H.; Berger, M.R. Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother. Pharmacol., 1998, 41, 210-216.
45. Konstantinov, S.M.; Topashka-Ancheva, M.; Benner, A.; Berger, M.R. Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer, 1998, 77, 778-786.
46. Konstantinov, S.M.; Eibl, H.; Berger, M.R. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br. J. Haematol., 1999, 107, 365-380.
47. Konstantinov, S.M.; Berger, M.R. Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines. Cancer Lett., 1999, 144, 153-160.
48. Kugler, W.; Buchholz, F.; Köhler, F.; Eibl, H.; Lakomek, M.; Erdlenbruch, B. Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: Consequences for erucylphosphocholine-induced apoptosis. Apoptosis, 2005, 10, 1163-1174.
49. Fiegl, M.; Lindner, L.H.; Juergens, M.; Eibl, H.; Hiddemann, W.; Braess, J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother. Pharmacol., 2008, 62, 321-329.
50. Takai, N.; Ueda, T.; Nasu, K.; Narahara, H. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol. Oncol., 2008, 111, 336-343.
51. Königs, S.K.; Pallasch, C.P.; Lindner, L.H.; Schwamb, J.; Schulz, A.; Brinker, R.; Claasen, J.; Veldurthy, A.; Eibl, H.; Hallek, M.; Wendtner, C.M. Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk. Res., 2010, 34, 1064-1069.
52. Mollinedo, F.; De la Iglesia-Vicente, J.; Gajate, C.; De Mendoza, A.; Villa-Pulgarin J.A., De Frias&, M., Roué&, G., Gil&, J., Colomer&, D., Campanero&, M.A., Blanco-Prieto&, M.J& In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res., 2010, 16, 2046-2054.
53. Rudner, J.; Ruiner, C.E.; Handrick, R.; Eibl, H.J.; Belka, C.; Jendrossek, V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat. Oncol., 2010, 5, 108.
54. Yosifov, D.Y.; Todorov, P.T.; Zaharieva, M.M.; Georgiev, K.D.; Pilicheva, B.A.; Konstantinov, S.M.; Berger, M.R. Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother. Pharmacol., 2011, 67, 13-25.
55. Jendrossek, V.; Kugler, W.; Erdlenbruch, B.; Eibl, H.; Lang, F.; Lakomek, M. Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: Involvement of caspase activation and mitochondrial alterations. Anticancer Res., 2001, 21, 3389-3396.
56. Momota, H.; Nerio, E.; Holland, E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res., 2005, 65, 7429-7435
57. Kugler, W.; Erdlenbruch, B.; Jünemann, A.; Heinemann, D.; Eibl, H.; Lakomek, M. Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signaling and caspase activation. J. Neurochem., 2002, 82, 1160-1170.
58. Bagley, R.G.; Kurtzberg, L.; Rouleau, C.; Yao, M.; Teicher, B.A. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother. Pharmacol., 2011, 68, 1537-1546.
59. Vehmeyer, K.; Kim, D.J.; Nagel, G.A.; Eibl, H.; Unger, C. Effect of ether lipids on mouse granulocyte-macrophage progenitor cells. Cancer Chemother. Pharmacol., 1989, 24, 58-60.
60. Pronk, L.C.; Planting, A.S.; Oosterom, R.; Drogendijk, T.E.; Stoter, G.; Verweij J. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. Eur. J. Cancer, 1994, 30A, 1019-1022.
61. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria in cancer cells: What is so special about them? Trends Cell Biol., 2008, 18, 165-173.
62. Hac-Wydro, K.; Dynarowicz-Łatka, P. Effect of edelfosine on tumor and normal cells model membranes - A comparative study. Colloids Surf. B Biointerfaces, 2010, 76, 366-369.
63. Berger, M.R.; Eibl, H. Erucylphosphocholine is a second generation alkylphosphocholine (APC). Proc. Am. Assoc. Cancer Res. 1992, 33, 416 (abstract 2483).
64. Berger, M.R.; Yanapirut, P.; Reinhardt, M.; Klenner, T.; Scherf, H.R.; Schmeiser, H.H.; Eibl, H. Antitumor activity of alkylphosphocholines and analogs in methylnitrosourea-induced rat mammary carcinomas. Prog. Exp. Tumor Res., 1992, 34, 98-115.
65. Erdlenbruch, B.; Jendrossek, V.; Eibl, H.; Lakomek, M. Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats. Exp. Brain Res., 2000 135, 417-422
66. Erdlenbruch, B.; Jendrossek, V.; Kugler, W.; Eibl, H.; Lakomek, M. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother. Pharmacol., 2002, 50, 299-304.
67. Henke, G.; Lindner, L.H.; Vogeser, M.; Eibl, H.J.; Wörner, J.; Müller, A.C.; Bamberg, M.; Wachholz, K.; Belka, C.; Jendrossek, V. Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy. Radiat. Oncol., 2009, 4, 46.
68. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26, 239-257.
69. Evan, G.I.; Vousden, K.H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411, 342-348.
70. Díez, J.; Walter, D.; Muñoz-Pinedo, C.; Gabaldón, T. DeathBase: a database on structure, evolution and function of proteins involved in apoptosis and other forms of cell death. Cell Death Differ., 2010, 17, 735-736.
71. Galluzzi, L.; Maiuri, M.C.; Vitale, I.; Zischka, H.; Castedo, M.; Zitvogel, L.; Kroemer, G. Cell death modalities: Classification and pathophysiological implications. Cell Death Differ., 2007, 14, 1237-1243.
72. Lüthi, A.U.; Martin, S.J. The CASBAH: A searchable database of caspase substrates. Cell Death Differ., 2007, 14, 641-650.
73. Guicciardi, M.E.; Gores, G.J. Life and death by death receptors. FASEB J., 2009, 23, 1625-1637.
74. Mahmood, Z.; Shukla, Y. Death receptors: Targets for cancer therapy. Exp. Cell Res., 2010, 316, 887-899.
75. Acehan, D.; Jiang, X.; Morgan, D.G.; Heuser, J.E.; Wang, X.; Akey, C.W. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell., 2002, 9, 423-432.
76. Blaineau, S.V.; Aouacheria, A. BCL2DB: Moving 'helix-bundled' BCL-2 family members to their database. Apoptosis, 2009, 14, 923-925.
77. Lessene, G.; Czabotar, P.E.; Colman, P.M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov., 2008, 7, 989-1000.
78. Galluzzi, L.; Morselli, E.; Kepp, O.; Tajeddine, N.; Kroemer, G. Targeting p53 to mitochondria for cancer therapy. Cell Cycle, 2008, 7, 1949-1955.
79. Jendrossek, V.; Müller, I.; Eibl, H.; Belka, C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene, 2003, 22, 2621-2631.
80. Kugler, W.; Veenman, L.; Shandalov, Y.; Leschiner, S.; Spanier, I.; Lakomek, M.; Gavish, M. Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell. Oncol., 2008, 30, 435-450.
81. Levin, E.; Premkumar, A.; Veenman, L.; Kugler, W.; Leschiner, S.; Spanier, I.; Weisinger, G., Lakomek, M.; Weizman, A.; Snyder, S.H.; Pasternak, G.W.; Gavish, M. The peripheral-type benzodiazepine receptor and tumorigenicity: Isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry, 2005, 44, 9924-9935.
82. Veenman, L.; Alten, J.; Linnemannstöns, K.; Shandalov, Y.; Zeno, S.; Lakomek, M.; Gavish, M.; Kugler, W. Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. Apoptosis, 2010, 15, 753-768.
83. Caballero, B.; Veenman, L.; Gavish, M. Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes. Recent Pat. Endocr. Metab. Immune Drug Discov., 2013, 7, 86-101.
84. Veenman, L.; Shandalov, Y.; Gavish, M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J. Bioenerg. Biomembr., 2008, 40, 199-205.
85. Jänicke, R.U.; Sprengart, M.L.; Wati, M.R.; Porter, A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 1998, 273, 9357-9360.
86. von Haefen, C.; Wieder, T.; Essmann, F.; Schulze-Osthoff, K.; Dörken, B.; Daniel, P.T. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene, 2003, 22, 2236-2247.
87. Wesselborg, S.; Engels, I.H.; Rossmann, E.; Los, M.; Schulze-Osthoff, K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood, 1999, 93, 3053-3063.
88. Slee, E.A.; Keogh, S.A.; Martin, S.J. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: A potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ., 2000, 7, 556-565.
89. Fujita, E.; Egashira, J.; Urase, K.; Kuida, K.; Momoi, T. Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo. Cell Death Differ., 2001, 8, 335-344.
90. Zou, H.; Yang, R.; Hao, J.; Wang, J.; Sun, C.; Fesik, S.W.; Wu, J.C.; Tomaselli, K.J.; Armstrong, R.C. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J. Biol. Chem., 2003, 278, 8091-8098.
91. Paroni, G.; Henderson, C.; Schneider, C.; Brancolini, C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J. Biol. Chem., 2001, 276, 21907-21915.
92. Srinivasula, S.M.; Ahmad, M.; Fernandes-Alnemri, T.; Alnemri, E.S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell., 1998, 1, 949-957.
93. Bouchier-Hayes, L.J. The role of caspase-2 in stress-induced apoptosis. Cell. Mol. Med., 2010, 14, 1212-1224.
94. Krumschnabel, G.; Sohm, B.; Bock, F.; Manzl, C.; Villunger, A. The enigma of caspase-2: the laymen's view. Cell Death Differ., 2009, 16, 195-207.
95. Kumar, S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? Nat. Rev. Cancer, 2009, 9, 897-903.
96. Slee, E.A.; Adrain, C.; Martin, S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem., 2001, 276, 7320-7326.
97. Ruchaud, S.; Korfali, N.; Villa, P.; Kottke, T.J.; Dingwall, C.; Kaufmann, S.H.; Earnshaw, W.C. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J., 2002, 21, 1967-1977.
98. Ferrando-May, E.; Cordes, V.; Biller-Ckovric, I.; Mirkovic, J.; Görlich, D.; Nicotera, P. Caspases mediate nucleoporin cleavage, but not early redistribution of nuclear transport factors and modulation of nuclear permeability in apoptosis. Cell Death Differ., 2001, 8, 495-505.
99. Pinton, P.; Giorgi, C.; Siviero, R.; Zecchini, E.; Rizzuto, R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene, 2008, 27, 6407-6418.
100. Handrick, R.; Rudner, J.; Müller, I.; Eibl, H.; Belka, C.; Jendrossek, V. Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localisation. Biochem. Pharmacol., 2005, 70, 837-850.
101. Braestrup, C.; Squires, R.F. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc. Natl. Acad. Sci. USA, 1977, 74, 3805-3809.
102. Cosenza-Nashat, M.; Zhao, M.L.; Suh, H.S.; Morgan, J.; Natividad, R.; Morgello, S.; Lee, S.C. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol. Appl. Neurobiol., 2009, 35, 306-328.
103. Verma, A.; Snyder, S.H. Peripheral-type benzodiazepine receptors. Annu. Rev. Pharmacol. Toxicol., 1989, 29, 307-322.
104. Gavish, M.; Bachman, I.; Shoukrun, R.; Katz, Y.; Veenman, L.; Weisinger, G.; Weizman, A. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev., 1999, 51, 629-650.
105. Papadopoulos, V.; Baraldi, M.; Guilarte, T.R.; Knudsen, T.B.; Lacapère, J.J.; Lindemann, P.; Norenberg, M.D.; Nutt, D.; Weizman, A.; Zhang, M.R.; Gavish, M. Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci., 2006, 27, 402-409.
106. Veenman, L.; Papadopoulos, V.; Gavish, M. Channel-like functions of the 18-kDa translocator protein (TSPO): Regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr. Pharm. Des., 2007, 13, 2385-2405.
107. Bernassau, J.M.; Reversat, J.L.; Ferrara, P.; Caput, D.; Lefur, G. A 3D model of the peripheral benzodiazepine receptor and its implication in intra mitochondrial cholesterol transport. J. Mol. Graph., 1993, 11, 236-244, 235.
108. Anholt, R.R.; Pedersen, P.L.; De Souza, E.B.; Snyder, S.H. The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J. Biol. Chem., 1986, 261, 576-583.
109. Olson, J.M.; Ciliax, B.J.; Mancini, W.R.; Young, A.B. Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes. Eur. J. Pharmacol., 1988, 152, 47-53.
110. O'Beirne, G.B.; Woods, M.J.; Williams, D.C. Two subcellular locations for peripheral-type benzodiazepine acceptors in rat liver. Eur. J. Biochem., 1990, 188, 131-138.
111. Hardwick, M.; Fertikh, D.; Culty, M.; Li, H.; Vidic, B.; Papadopoulos, V. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res., 1999, 59, 831-842.
112. Brown, R.C.; Degenhardt, B.; Kotoula, M.; Papadopoulous, V. Location-dependent role of the human glioma cell peripheral-type benzodiazepine receptor in proliferation and steroid biosynthesis. Cancer Lett., 2000, 156,125-132.
113. Corsi, L.; Geminiani, E.; Avallone, R.; Baraldi, M. Nuclear location-dependent role of peripheral benzodiazepine receptor (PBR) in hepatic tumoral cell lines proliferation. Life Sci., 2005, 76, 2523-2533.
114. Guidotti, A.; Forchetti, C.M.; Corda, M.G.; Konkel, D.; Bennett, C.D.; Costa, E. Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc. Natl. Acad. Sci. USA, 1983, 80, 3531-3535.
115. Verma, A.; Nye, J.S.; Snyder, S.H. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl. Acad. Sci. USA, 1987, 84, 2256-2260.
116. Veenman, L.; Gavish, M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther., 2006, 110, 503-524.
117. Rothstein, J.D.; Garland, W.; Puia, G.; Guidotti, A.; Weber, R.J.; Costa, E. Purification and characterization of naturally occurring benzodiazepine receptor ligands in rat and human brain. J. Neurochem., 1992, 58, 2102-2115.
118. Galiègue, S.; Tinel, N.; Casellas, P. The peripheral benzodiazepine receptor: A promising therapeutic drug target. Curr. Med. Chem., 2003, 10, 1563-1572.
119. Decaudin, D. Peripheral benzodiazepine receptor and its clinical targeting. Anticancer Drugs, 2004, 15, 737-745.
120. McEnery, M.W.; Snowman, A.M.; Trifiletti, R.R.; Snyder, S.H. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc. Natl. Acad. Sci. USA, 1992, 89, 3170-3174.
121. Zoratti, M.; Szabò, I. The mitochondrial permeability transition. Biochim. Biophys. Acta, 1995, 1241, 139-176.
122. Galiègue, S.; Jbilo, O.; Combes, T.; Bribes, E.; Carayon, P.; Le Fur, G.; Casellas, P. Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepine receptor. J. Biol. Chem., 1999, 274, 2938-2952.
123. West, L.A.; Horvat, R.D.; Roess, D.A.; Barisas, B.G.; Juengel, J.L.; Niswender, G.D. Steroidogenic acute regulatory protein and peripheral-type benzodiazepine receptor associate at the mitochondrial membrane. Endocrinology, 2001, 142, 502-505.
124. Li, H.; Degenhardt, B.; Tobin, D.; Yao, Z.X.; Tasken, K.; Papadopoulos, V. Identification, localization, and function in steroidogenesis of PAP7: A peripheral-type benzodiazepine receptor- and PKA (RIalpha)-associated protein. Mol. Endocrinol., 2001, 15, 2211-2228.
125. Liu, J.; Li, H.; Papadopoulos, V. PAP7, a PBR/PKA-RIalpha-associated protein: A new element in the relay of the hormonal induction of steroidogenesis. J. Steroid Biochem. Mol. Biol., 2003, 85, 275-283.
126. Blahos, J.; Whalin, M.E.; Krueger, K.E. Identification and purification of a 10-kilodalton protein associated with mitochondrial benzodiazepine receptors. J. Biol. Chem., 1995, 270, 20285-20291.
127. Verrier, F.; Mignotte, B.; Jan, G.; Brenner, C. Study of PTPC composition during apoptosis for identification of viral protein target. Ann. N. Y. Acad. Sci., 2003, 1010, 126-142.
128. Guilarte, T.R.; Kuhlmann, A.C.; O'Callaghan, J.P.; Miceli, R.C. Enhanced expression of peripheral benzodiazepine receptors in trimethyltin-exposed rat brain: a biomarker of neurotoxicity. Neurotoxicology, 1995, 16, 441-450.
129. Chen, M.K.; Guilarte, T.R. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol. Ther., 2008, 118, 1-17.
130. Banati, R.B. Visualising microglial activation in vivo. Glia, 2002, 40, 206-217.
131. Le Goascogne, C.; Eychenne, B.; Tonon, M.C.; Lachapelle, F.; Baumann, N.; Robel, P. Neurosteroid progesterone is up-regulated in the brain of jimpy and shiverer mice. Glia, 2000, 29, 14-24.
132. Chen, M.K.; Baidoo, K.; Verina, T.; Guilarte, T.R. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain, 2004, 127, 1379-1392.
133. Krueger, K.E.; Papadopoulos, V. Peripheral-type benzodiazepine receptors mediate translocation of cholesterol from outer to inner mitochondrial membranes in adrenocortical cells. J. Biol. Chem., 1990, 265, 15015-15022.
134. Lacapère, J.J.; Papadopoulos, V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids, 2003, 68, 569-585.
135. Papadopoulos, V.; Lecanu, L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp. Neurol., 2009, 219, 53-57.
136. Bode, J.; Veenman, L.; Caballero, B.; Lakomek, M.; Kugler, W.; Gavish, M. The 18 kDa translocator protein influences angiogenesis, as well as aggressiveness, adhesion, migration, and proliferation of glioblastoma cells. Pharmacogenet. Genom., 2012, 22, 538-550.
137. James, M.L.; Selleri, S.; Kassiou, M. Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem., 2006, 13, 1991-2001.
138. Katz, Y.; Eitan, A.; Amiri, Z.; Gavish, M. Dramatic increase in peripheral benzodiazepine binding sites in human colonic adenocarcinoma as compared to normal colon. Eur. J. Pharmacol., 1988, 148, 483-484.
139. Van Dort, M.E.; Ciliax, B.J.; Gildersleeve, D.L.; Sherman, P.S.; Rosenspire, K.C.; Young, A.B.; Junck, L.; Wieland, D.M. Radioiodinated benzodiazepines: agents for mapping glial tumors. J. Med. Chem., 1988, 31, 2081-2086.
140. Venturini, I.; Alho, H.; Podkletnova, I.; Corsi, L.; Rybnikova, E.; Pellicci, R.; Baraldi, M.; Pelto-Huikko, M.; Helén, P.; Zeneroli, M.L. Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver. Life Sci., 1999, 65, 2223-2231.
141. Venturini, I.; Zeneroli, M.L.; Corsi, L.; Avallone, R.; Farina, F.; Alho, H.; Baraldi, C.; Ferrarese, C.; Pecora, N.; Frigo, M.; Ardizzone, G.; Arrigo, A.; Pellicci, R.; Baraldi, M. Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma. Life Sci., 1998, 63, 1269-1280.
142. Veenman, L.; Levin, E.; Weisinger, G.; Leschiner, S.; Spanier, I.; Snyder, S.H.; Weizman, A.; Gavish, M. Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochem. Pharmacol., 2004, 68, 689-698.
143. Benavides, J.; Cornu, P.; Dennis, T.; Dubois, A.M.; Hauw, J.J.; MacKenzie, E.T.; Sazdovitch, V.; Scatton, B. Imaging of human brain lesions with an omega 3 site radioligand. Ann. Neurol. 1988, 24, 708-712.
144. Junck, L.; Olson, J.M.; Ciliax, B.J.; Koeppe, R.A.; Watkins, G.L.; Jewett, D.M.; McKeever, P.E.; Wieland, D.M.; Kilbourn, M.R., Starosta-Rubinstein, S.; et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann. Neurol., 1989, 26, 752-758.
145. Black, K.L.; Ikezaki, K.; Santori, E.; Becker, D.P.; Vinters, H.V. Specific high-affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man. Cancer, 1990, 65, 93-97.
146. Ikezaki, K.; Black, K.L.; Santori, E.M.; Smith, M.L.; Becker, D.P.; Payne, B.A.; Toga, A.W. Three-dimensional comparison of peripheral benzodiazepine binding and histological findings in rat brain tumor. Neurosurgery, 1990, 27, 78-82.
147. Pappata, S.; Cornu, P.; Samson, Y.; Prenant, C.; Benavides, J.; Scatton, B.; Crouzel, C.; Hauw, J.J.; Syrota, A. PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J. Nucl. Med., 1991, 32, 1608-1610.
148. Gildersleeve, D.L.; Lin, T.Y.; Wieland, D.M.; Ciliax, B.J.; Olson, J.M.; Young, A.B. Synthesis of a high specific activity 125I-labeled analog of PK 11195, potential agent for SPECT imaging of the peripheral benzodiazepine binding site. Int. J. Rad. Appl. Instrum. B., 1989, 16, 423-429.
149. Manning, H.C.; Goebel, T.; Thompson, R.C.; Price, R.R.; Lee, H.; Bornhop, D.J. Targeted molecular imaging agents for cellular-scale bimodal imaging. Bioconjug. Chem., 2004, 15, 1488-1495.
150. Selleri, S.; Gratteri, P.; Costagli, C.; Bonaccini, C.; Costanzo, A.; Melani, F.; Guerrini, G.; Ciciani, G.; Costa, B.; Spinetti, F.; Martini, C.; Bruni, F. Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation. Bioorg. Med. Chem., 2005, 13, 4821-4834.
151. Laquintana, V.; Denora, N.; Lopedota, A.; Suzuki, H.; Sawada, M.; Serra, M.; Biggio, G.; Latrofa, A.; Trapani, G.; Liso, G. N-benzyl-2-(6,8-dichloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N-(6-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)hexyl)acetamide as a new fluorescent probe for peripheral benzodiazepine receptor and microglial cell visualization. Bioconjug. Chem., 2007, 18, 1397-1407.
152. Taliani, S.; Simorini, F.; Sergianni, V.; La Motta, C.; Da Settimo, F.; Cosimelli, B.; Abignente, E.; Greco, G.; Novellino, E.; Rossi, L.; Gremigni, V.; Spinetti, F.; Chelli, B.; Martini, C. New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation. J. Med. Chem., 2007, 50, 404-407.
153. Yamasaki, T.; Kumata, K.; Yanamoto, K.; Hatori, A.; Takei, M.; Nakamura, Y.; Koike, S.; Ando, K.; Suzuki, K.; Zhang, M.R. Imaging of peripheral-type benzodiazepine receptor in tumor: in vitro binding and in vivo biodistribution of N-benzyl-N-[(11)C]methyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9H-purin-9-yl)acetamide. Nucl. Med. Biol., 2009, 36, 801-809.
154. Samuelson, L.E.; Dukes, M.J.; Hunt, C.R.; Casey, J.D.; Bornhop, D.J. TSPO targeted dendrimer imaging agent: synthesis, characterization, and cellular internalization. Bioconjug. Chem., 2009, 20, 2082-1089.
155. Bertomeu, T.; Zvereff, V.; Ibrahim, A.; Zehntner, S.P.; Aliaga, A.; Rosa-Neto, P.; Bedell, B.J.; Falardeau, P.; Gourdeau, H. TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation. Biochem. Pharmacol., 2010, 80, 1572-1579.
156. Buck, J.R.; McKinley, E.T.; Hight, M.R.; Fu, A.; Tang, D.; Smith, R.A.; Tantawy, M.N.; Peterson, T.E.; Colvin, D.; Ansari, M.S.; Baldwin, R.M.; Zhao, P.; Guleryuz, S.; Manning, H.C. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J. Nucl. Med., 2011, 52, 107-114.
157. Cornu, P.; Benavides, J.; Scatton, B.; Hauw, J.J.; Philippon, J. Increase in omega 3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumours. A quantitative autoradiography study. Acta Neurochir. (Wien), 1992, 119, 146-152.
158. Takada, A.; Mitsuka, S.; Diksic, M.; Yamamoto, Y.L. Autoradio-graphic study of peripheral benzodiazepine receptors in animal brain tumor models and human gliomas. Eur. J. Pharmacol., 1992, 228, 131-139.
159. Vlodavsky, E.; Soustiel, J.F. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J. Neurooncol., 2007, 81, 1-7.
160. Miyazawa, N.; Hamel, E.; Diksic, M. Assessment of the peripheral benzodiazepine receptors in human gliomas by two methods. J. Neurooncol., 1998, 38, 19-26.
161. Takaya, S.; Hashikawa, K.; Turkheimer, F.; Mottram, N.; Deprez, M.; Ishizu, K.; Kawashima, H.; Akiyama, H.; Fukuyama, H.; Banati, R.B.; Roncaroli, F. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J. Neurooncol., 2007, 85, 95-103.
162. Ferrarese, C.; Appollonio, I.; Frigo, M.; Gaini, S.M.; Piolti, R.; Frattola, L. Benzodiazepine receptors and diazepam-binding inhibitor in human cerebral tumors. Ann. Neurol., 1989, 26, 564-568.
163. Miettinen, H.; Kononen, J.; Haapasalo, H.; Helén, P.; Sallinen, P.; Harjuntausta, T.; Helin, H.; Alho, H. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: Relationship to cell proliferation. Cancer Res., 1995, 55, 2691-2695.
164. Pollard, C.; Nitz, M.; Baras, A.; Williams, P.; Moskaluk, C.; Theodorescu, D. Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am. J. Pathol., 2009, 175, 1824-1830.
165. Weisinger, G.; Kelly-Hershkovitz, E.; Veenman, L.; Spanier, I.; Leschiner, S.; Gavish, M. Peripheral benzodiazepine receptor antisense knockout increases tumorigenicity of MA-10 Leydig cells in vivo and in vitro. Biochemistry, 2004, 43, 12315-12321.
166. Shiraishi, T.; Black, K.L.; Ikezaki, K.; Becker, D.P. Peripheral benzodiazepine induces morphological changes and proliferation of mitochondria in glioma cells. J. Neurosci. Res., 1991, 30, 463-474.
167. Rechichi, M.; Salvetti, A.; Chelli, B.; Costa, B.; Da Pozzo, E.; Spinetti, F.; Lena, A.; Evangelista, M.; Rainaldi, G.; Martini, C.; Gremigni, V.; Rossi, L. TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim. Biophys. Acta, 2008, 1782, 118-25.
168. Decaudin, D.; Castedo, M.; Nemati, F.; Beurdeley-Thomas, A.; De Pinieux, G.; Caron, A.; Pouillart, P.; Wijdenes, J.; Rouillard, D.; Kroemer, G.; Poupon, M.F. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res., 2002, 62, 1388-1393.
169. Chelli, B.; Lena, A.; Vanacore, R.; Da Pozzo, E.; Costa, B.; Rossi, L.; Salvetti, A.; Scatena, F.; Ceruti, S.; Abbracchio, M.P.; Gremigni, V.; Martini, C. Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem. Pharmacol., 2004, 68, 125-134.
170. Chelli, B.; Salvetti, A.; Da Pozzo, E.; Rechichi, M.; Spinetti, F.; Rossi, L.; Costa, B.; Lena, A; Rainaldi, G.; Scatena, F.; Vanacore, R.; Gremigni, V.; Martini, C. PK 11195 differentially affects cell survival in human wild-type and 18 kDa translocator protein-silenced ADF astrocytoma cells. J. Cell. Biochem., 2008, 105, 712-723.
171. Kupczyk-Subotkowska, L.; Siahaan, T.J.; Basile, A.S.; Friedman, H.S.; Higgins, P.E.; Song, D.; Gallo, J.M. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. J. Med. Chem., 1997, 40, 1726-1730.
172. Lavicka, J.; Sarisský, M.; Mirossay, A.; Sulla, I.; Mojzis, J.; Mirossay, L. Diazepam enhances etoposide-induced cytotoxicity in U-87 MG human glioma cell line. Fundam. Clin. Pharmacol., 2001, 15, 201-207.
173. Sarissky, M.; Lavicka, J.; Kocanová, S.; Sulla, I.; Mirossay, A.; Miskovsky, P.; Gajdos, M.; Mojzis, J.; Mirossay, L. Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells. Neoplasma, 2005, 52, 352-359.
174. Musacchio, T.; Laquintana, V.; Latrofa, A.; Trapani, G.; Torchilin, V.P. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: Synergistic anticancer effect. Mol. Pharm., 2009, 6, 468-479.
175. Ferrarese, C.; Pierpaoli, C.; Linfante, I.; Bobo, R.H.; Guthrie, B.; Kufta, C.; Duhaney, M.O.; Melisi, J.; Fulham, M.J. Peripheral benzodiazepine receptors and glucose metabolism in human gliomas. J. Neurooncol., 1994, 22, 15-22.
176. Zeno, S.; Zaaroor, M.; Leschiner, S.; Veenman, L.; Gavish, M. CoCl(2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells. Biochemistry, 2009, 48, 4652-4661.
177. Panickar, K.S.; Jayakumar, A.R.; Rama Rao, K.V.; Norenberg, M.D. Downregulation of the 18-kDa translocator protein: effects on the ammonia-induced mitochondrial permeability transition and cell swelling in cultured astrocytes. Glia, 2007, 55, 1720-1727.
178. Veenman, L., Gavish, M. The role of 18 kDa mitochondrial translocator protein (TSPO) in programmed cell death, and effects of steroids on TSPO expression. Curr. Mol. Med., 2012, 12, 398-412.
179. Bono, F.; Lamarche, I.; Prabonnaud, V.; Le Fur, G.; Herbert, J.M. Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem. Biophys. Res. Commun., 1999, 265, 457-461.
180. Morris, R.L.; Varnes, M.E.; Kenney, M.E.; Li, Y.S.; Azizuddin, K.; McEnery, M.W.; Oleinick, N.L. The peripheral benzodiazepine receptor in photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Photochem. Photobiol., 2002, 75, 652-661.
181. Strohmeier, R.; Roller, M.; Sänger, N.; Knecht, R.; Kuhl, H. Modulation of tamoxifen-induced apoptosis by peripheral benzodiazepine receptor ligands in breast cancer cells. Biochem. Pharmacol., 2002, 64, 99-107.
182. Marselli, L.; Trincavelli, L.; Santangelo, C.; Lupi, R.; Del Guerra, S.; Boggi, U.; Falleni, A.; Gremigni, V.; Mosca, F.; Martini, C.; Dotta, F.; Di Mario, U.; Del Prato, S.; Marchetti, P. The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. Eur. J. Endocrinol., 2004, 151, 207-214.
183. Shargorodsky, L.; Veenman, L.; Caballero, B.; Pe'er, Y.; Leschiner, S.; Bode, J.; Gavish, M. The nitric oxide donor sodium nitroprusside requires the 18 kDa translocator protein to induce cell death. Apoptosis, 2012, 17, 647-665.
184. Shoukrun, R.; Veenman, L.; Shandalov, Y.; Leschiner, S.; Spanier, I.; Karry, R.; Katz, Y.; Weisinger, G.; Weizman, A.; Gavish, M. The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line. Pharmacogenet. Genom., 2008, 18, 977-988.
185. Costa, B.; Salvetti, A.; Rossi, L.; Spinetti, F.; Lena, A.; Chelli, B.; Rechichi, M.; Da Pozzo, E.; Gremigni, V.; Martini C. Peripheral benzodiazepine receptor: characterization in human T-lymphoma Jurkat cells. Mol. Pharmacol., 2006, 69, 37-44.
186. Caballero, B.; Veenman, L.; Bode, J.; Leschiner, S.; Gavish, M. Concentration-dependent bimodal effects of TSPO specific ligands on cell death induced by ammonium chloride. CNS Neurol. Disord. Drug Targets, 2013 [Epub ahead of print].
187. Baraldi, M.; Avallone, R.; Corsi, L.; Venturini, I.; Baraldi, C.; Zeneroli, M.L. Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. Metab. Brain Dis., 2009, 24, 81-93.
188. Selleri, S.; Bruni, F.; Costagli, C.; Costanzo, A.; Guerrini, G.; Ciciani, G.; Costa, B.; Martini, C. 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorg. Med. Chem., 2001, 9, 2661-2671.
189. Primofiore, G.; Da Settimo, F.; Taliani, S.; Simorini, F.; Patrizi, M.P.; Novellino, E.; Greco, G.; Abignente, E.; Costa, B.; Chelli, B.; Martini, C. N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J. Med. Chem., 2004, 47, 1852-1855.
190. Danovich, L.; Veenman, L.; Leschiner, S.; Lahav, M.; Shuster, V.; Weizman, A.; Gavish, M. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur. Neuropsychopharmacol., 2008, 18, 24-33.
191. Da Settimo, F.; Simorini, F.; Taliani, S.; La Motta, C.; Marini, A.M.; Salerno, S.; Bellandi, M.; Novellino, E.; Greco, G.; Cosimelli, B.; Da Pozzo, E.; Costa, B.; Simola, N.; Morelli, M.; Martini, C. Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J. Med. Chem., 2008, 51, 5798-5806.
192. Mazurika, C.; Veenman, L.; Weizman, R.; Bidder, M.; Leschiner, S.; Golani, I.; Spanier, I.; Weisinger, G.; Gavish, M. Estradiol modulates uterine 18 kDa translocator protein gene expression in uterus and kidney of rats. Mol. Cell Endocrinol., 2009, 307, 43-49.
193. Miccoli, L.; Oudard, S.; Beurdeley-Thomas, A.; Dutrillaux, B.; Poupon, M.F. Effect of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide (PK11195), a specific ligand of the peripheral benzodiazepine receptor, on the lipid fluidity of mitochondria in human glioma cells. Biochem. Pharmacol., 1999, 58, 715-721.
194. Olson, J.M.; McNeel, W.; Young, A.B.; Mancini, W.R. Localization of the peripheral-type benzodiazepine binding site to mitochondria of human glioma cells. J. Neurooncol., 1992, 13, 35-42.
195. Veenman, L.; Bode, J.; Gaitner, M.; Caballero, B.; Pe'er, Y.; Zeno, S., Kietz, S.; Kugler, W.; Lakomek, M.; Gavish, M. Effects of TSPO knockdown on glutamate receptors, transporters, and metabolism, and on cell viability affected by glutamate. Pharmacogenet. Genom., 2012, 22, 606-619.
196. Dehnhardt, M.; Palm, C.; Vieten, A.; Bauer, A.; Pietrzyk, U. Quantifying the A1AR distribution in peritumoural zones around experimental F98 and C6 rat brain tumours. J. Neurooncol., 2007, 85, 49-63.
197. Takeda N, Diksic M, Yamamoto YL. The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. Cancer, 1996, 77, 1167-1179.
198. Guo, P.; Ma, J.; Li, S.; Guo, Z.; Adams, A.L.; Gallo, J.M. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother. Pharmacol., 2001, 48, 169-176.
199. Pretner, E.; Amri, H.; Li, W.; Brown, R.; Lin, C.S.; Makariou, E.; Defeudis, F.V.; Drieu, K.; Papadopoulos, V. Cancer-related overexpression of the peripheral-type benzodiazepine receptor and cytostatic anticancer effects of Ginkgo biloba extract (EGb 761). Anticancer Res., 2006, 26, 9-22.
200. Laquintana, V.; Denora, N.; Musacchio, T.; Lasorsa, M.; Latrofa, A.; Trapani, G. Peripheral benzodiazepine receptor ligand-PLGA polymer conjugates potentially useful as delivery systems of apoptotic agents. J. Control Release, 2009, 137, 185-195.
201. Bisland, S.K.; Goebel, E.A.; Hassanali, N.S.; Johnson, C.; Wilson, B.C. Increased expression of mitochondrial benzodiazepine receptors following low-level light treatment facilitates enhanced protoporphyrin IX production in glioma-derived cells in vitro. Lasers Surg. Med., 2007, 39, 678-684.
202. Zeno, S.; Veenman, L.; Katz, Y.; Bode, J.; Gavish, M.; Zaaroor, M. The 18 kDa mitochondrial translocator protein (TSPO) prevents accumulation of protoporphyrin IX. Involvement of reactive oxygen species (ROS). Curr. Mol. Med., 2012, 12, 494-501.
203. Vanhee, C.; Zapotoczny, G.; Masquelier, D.; Ghislain, M.; Batoko, H. The Arabidopsis multistress regulator TSPO is a heme binding membrane protein and a potential scavenger of porphyrins via an autophagy-dependent degradation mechanism. Plant Cell., 2011, 23, 785-805.
204. Rampon, C.; Bouzaffour, M.; Ostuni, M.A.; Dufourcq, P.; Girard, C.; Freyssinet, J.M.; Lacapere, J.J.; Schweizer-Groyer, G.; Vriz, S. Translocator protein (18 kDa) is involved in primitive erythropoiesis in zebrafish. FASEB J., 2009, 23, 4181-4192.
205. Yeliseev, A.A.; Kaplan, S. A novel mechanism for the regulation of photosynthesis gene expression by the TspO outer membrane protein of Rhodobacter sphaeroides 2.4.1. J. Biol. Chem., 1999, 274, 21234-21243.
206. Jonas, E.A. Molecular participants in mitochondrial cell death channel formation during neuronal ischemia. Exp. Neurol., 2009, 218, 203-212.
207. Ryu, S.Y.; Peixoto, P.M.; Teijido, O.; Dejean, L.M.; Kinnally, K.W. Role of mitochondrial ion channels in cell death. Biofactors, 2010, 36, 255-263.
208. Maaser, K.; Höpfner, M.; Jansen, A.; Weisinger, G.; Gavish, M.; Kozikowski, A.P.; Weizman, A.; Carayon, P.; Riecken, E.O.; Zeitz, M.; Scherübl, H. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br. J. Cancer, 2001, 85, 1771-1780.
209. Veenman, L.; Weizman, A.; Weisinger, G.; Gavish, M. Expression and functions of the 18 kDa mitochondrial translocator protein (TSPO) in health and disease. In: Targeted Drug Delivery in Cancer Therapeutics; Firer, M.A., Ed.; Transworld Research Network: Kerala, India, 2010; pp. 49-84.
210. Garrido, C.; Galluzzi, L.; Brunet, M.; Puig, P.E.; Didelot, C.; Kroemer, G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ., 2006, 13, 1423-1433.
211. Handrick, R.; Rübel, A.; Faltin, H.; Eibl, H.; Belka, C.; Jendrossek, V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother. Oncol., 2006, 80, 199-206.
212. Furre, I.E.; Shahzidi, S.; Luksiene, Z.; Møller, M.T.; Borgen, E.; Morgan, J.; Tkacz-Stachowska, K.; Nesland, J.M.; Peng, Q. Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor in human leukemia cells. Cancer Res., 2005, 65, 11051-11060.
213. Ferlini, C.; Scambia, G.; Marone, M.; Distefano, M.; Gaggini, C.; Ferrandina, G.; Fattorossi, A.; Isola, G.; Benedetti Panici, P.; Mancuso, S. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br. J. Cancer, 1999, 79, 257-263.
214. Gupta, S.; Ahmad, N.; Mukhtar, H. Involvement of nitric oxide during phthalocyanine (Pc4) photodynamic therapy-mediated apoptosis. Cancer Res., 1998, 58, 1785-1788.
215. Choi, J.; Ifuku, M.; Noda, M.; Guilarte, T.R. Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia, 2011, 59, 219-230.
216. Rosenberg, N.; Rosenberg, O.; Weizman, A.; Leschiner, S.; Sakoury, Y.; Fares, F.; Soudry, M.; Weisinger, G.; Veenman, L.; Gavish, M. In vitro mitochondrial effects of PK 11195, a synthetic translocator protein 18 kDa (TSPO) ligand, in human osteoblast-like cells. J. Bioenerg. Biomembr., 2011, 43, 739-746.
217. Krestinina, O.V.; Grachev, D.E.; Odinokova, I.V.; Reiser, G.; Evtodienko, Y.V.; Azarashvili, T.S. Effect of peripheral benzodiazepine receptor (PBR/TSPO) ligands on opening of Ca2+-induced pore and phosphorylation of 3.5-kDa polypeptide in rat brain mitochondria. Biochemistry (Mosc), 2009, 74, 421-429.
218. Jiménez-López, J.M.; Ríos-Marco, P.; Marco, C.; Segovia, J.L.; Carrasco, M.P. Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis., 2010, 9, 33.
219. Van der Luit, A.H.; Vink, S.R.; Klarenbeek, J.B.; Perrissoud, D.; Solary, E.; Verheij, M.; Van Blitterswijk, W.J. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol. Cancer Ther., 2007, 6, 2337-2345.
220. Gajate, C.; Mollinedo, F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood, 2007, 109, 711-719.
221. Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One, 2009, 4, e5044.
222. Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene, 2009, 28, 3221-3234.
223. Stel, A.J.; Ten Cate, B.; Jacobs, S.; Kok, J.W.; Spierings, D.C.; Dondorff, M.; Helfrich, W.; Kluin-Nelemans, H.C.; De Leij, L.F.; Withoff, S.; Kroesen, B.J. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J. Immunol., 2007, 178, 2287-2295.
224. Berger, M.R.; Tsoneva, I.; Konstantinov, S.M.; Eibl, H. Induction of apoptosis by erucylphospho-N,N,N-trimethylammonium is associated with changes in signal molecule expression and location. Ann. N.Y. Acad. Sci., 2003, 1010, 307-310.
225. Carrasco, M.P.; Jiménez-López, J.M.; Ríos-Marco, P.; Segovia, J.L.; Marco, C. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogs. Br. J. Pharmacol., 2010, 160, 355-366.
226. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501.
227. Fan, Q.W.; Weiss, W.A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr. Top. Microbiol. Immunol., 2010, 347, 279-296.
228. Vasudevan, K.M.; Garraway, L.A. AKT signaling in physiology and disease. Curr. Top. Microbiol. Immunol., 2010, 347, 105-133.
229. Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2, 1093-1103.
230. Perona, R.; Sánchez-Pérez, I. Signalling pathways involved in clinical responses to chemotherapy. Clin. Transl. Oncol., 2007, 9, 625-633.
231. Dhillon, A.S.; Hagan, S.; Rath, O.M; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26, 3279-3290.
232. Kugler, W.; Erdlenbruch, B.; Otten, K.; Jendrossek, V.; Eibl, H.; Lakomek, M. MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. Int. J. Oncol., 2004, 25, 1721-1727.
233. Martelli, A.M.; Papa, V.; Tazzari, P.L.; Ricci, F.; Evangelisti, C.; Chiarini, F.; Grimaldi, C.; Cappellini, A.; Martinelli, G.; Ottaviani, E.; Pagliaro, P.; Horn, S.; Bäsecke, J.; Lindner, L.H.; Eibl, H.; McCubrey, J.A. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia, 2010, 24, 687-698.
234. Fulda, S.; Küfer, M.U.; Meyer, E.; van Valen, F.; Dockhorn-Dworniczak, B.; Debatin, K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 2001, 20, 5865-5877.
235. Grotzer, M.A.; Eggert, A.; Zuzak, T.J.; Janss, A.J.; Marwaha, S.; Wiewrodt, B.R.; Ikegaki, N.; Brodeur, G.M.; Phillips, P.C. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene, 2000, 19, 4604-4610.
236. Shivapurkar, N.; Toyooka, S.; Eby, M.T.; Huang, C.X.; Sathyanarayana, U.G.; Cunningham, H.T.; Reddy, J.L.; Brambilla, E.; Takahashi, T.; Minna, J.D.; Chaudhary, P.M.; Gazdar, A.F. Differential inactivation of caspase-8 in lung cancers. Cancer Biol. Ther., 2002, 1, 65-69.
237. Amatya, V.J.; Naumann, U.; Weller, M.; Ohgaki, H. TP53 promoter methylation in human gliomas. Acta Neuropathol. (Berl.), 2005, 110, 178-184.
238. Kitange, G.J.; Templeton, K.L.; Jenkins, R.B. Recent advances in the molecular genetics of primary gliomas. Curr. Opin. Oncol., 2003, 15, 197-203.
239. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature, 2000, 408, 307-310.
240. Knuefermann, C.; Lu, Y.; Liu, B.; Jin, W.; Liang, K.; Wu, L.; Schmidt, M.; Mills, G.B.; Mendelsohn, J.; Fan, Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene, 2003, 22, 3205-3212.
241. Di Cristofano, A.; Pandolfi, P.P. The multiple roles of PTEN in tumor suppression. Cell, 2000, 100, 387-390.
242. Frisk, T.; Foukakis, T.; Dwight, T.; Lundberg, J.; Hoog, A.; Wallin, G.; Eng, C.; Zedenius, J.; Larsson, C. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer, 2002, 35, 74-80.
243. Huang, H.; Cheville, J.C.; Pan, Y.; Roche, P.C.; Schmidt, L.J.; Tindall, D.J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem., 2001, 276, 38830-38836.
244. Georgieva, M.C.; Konstantinov, S.M.; Topashka-Ancheva, M.; Berger, M.R. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett., 2002, 182, 163-174.
245. Konstantinov, S.M.; Georgieva, M.C.; Topashka-Ancheva, M.; Eibl, H.; Berger, M.R. Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines. Mol. Cancer Ther., 2002, 1, 877-884.
246. Rübel, A.; Handrick, R.; Lindner, L.H.; Steiger, M.; Eibl, H.; Budach, W.; Belka, C.; Jendrossek, V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat. Oncol., 2006, 1, 6.
247. Henke, G.; Meier, V.; Lindner, L.H.; Eibl H.; Bamberg, M.; Belka, C.; Budach, W.; Jendrossek, V. Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice. Radiat Oncol., 2012, 7, 172.
248. Croft, S.L.; Seifert, K.; Duchêne, M. Antiprotozoal activities of phospholipid analogs. Mol. Biochem. Parasitol., 2003, 126, 165-172.
249. Mishra, J.; Saxena, A.; Singh, S. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem., 2007, 14, 1153-1169.
250. Eibl, K.H.; Fisher, S.K.; Lewis, G.P. Alkylphosphocholines: a new approach to inhibit cell proliferation in proliferative vitreoretinopathy. Dev. Ophthalmol., 2009, 44, 46-55.
251. Halestrap, A.P. What is the mitochondrial permeability transition pore? J. Mol. Cell. Cardiol., 2009, 46, 821-831.
252. Orrenius, S.; Zhivotovsky, B. Cardiolipin oxidation sets cytochrome c free. Nat. Chem. Biol., 2005, 1, 188-189.
253. Shoshan-Barmatz, V.; Keinan, N.; Abu-Hamad, S.; Tyomkin, D.; Aram, L. Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release of cytochrome c, AIF and Smac/Diablo. Biochim. Biophys. Acta, 2010, 1797, 1281-1291.
254. Martinez-Caballero, S.; Dejean, L.M.; Kinnally, M.S.; Oh, K.J.; Mannella, C.A.; Kinnally, K.W. Assembly of the mitochondrial apoptosis-induced channel, MAC. J. Biol. Chem., 2009, 284, 12235-12245.